Drug Epidemiology and Post-Marketing Surveillance

Spontaneous Reporting: The Analysis of Postmarketing Drug Surveillance Data at the U.S. Food and Drug Administration T.P. Gross. Pharmacovigilance in France B. Begaud. Traditional Clinical Epidemiology Methods as Applied to Pharmacoepidemiology: The Use of Cohort Studies in Pharmacoepidemiology T. Creagh-Kirk. Use of Automated Databases for Pharmacoepidemiology: Screening for Unknown Effects of Newly Marketed Drugs J.L. Carson, B.L. Strom. Hospital Pharmacoepidemiology: Hospital Data Sources J.K. Jones. New Methodologic Developments: Approaches to Evaluating Causation of Suspected Drug Reactions J.K. Jones. Pharmacoeconomics H. Glick, R. Kington. Selected Examples of Regulatory and Commercial Importance: The Triazolam Experience in 1979 in the Netherlands R.H.B. Meyboom. Eleven additional articles. Index.

[1]  R. Temple,et al.  Adverse effects of newly marketed drugs. , 1979, The New England journal of medicine.

[2]  K. N. Williams,et al.  Conceptualization and Measurement of Health for Adults in the Health Insurance Study: Vol. I, Model of Health and Methodology , 1979 .

[3]  Samuel Sá.  Apparent anaphylactic reaction to zomepirac (Zomax) , 1981 .

[4]  M H Liang,et al.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. , 1985, Arthritis and rheumatism.

[5]  J. Osterloh,et al.  Coma caused by trivial triazolam overdose. , 1985, The American journal of emergency medicine.

[6]  J. Fleming,et al.  Withdrawal regimen for triazolam-dependent patients. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  G. Guyatt,et al.  Measuring disease-specific quality of life in clinical trials. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[8]  B. Strom,et al.  Use of automated databases for pharmacoepidemiology research. , 1990, Epidemiologic reviews.